title: [Frequency and costs of hospital stays for hypoglycemia in France in 1995].
abstract: OBJECTIVE
  Diabetes is a highly prevalent chronic disease causing serious complications. Hypoglycemia is the most frequent, the most serious, and the most feared by patients and families. Hospitalization may be necessary and can be costly. The main objective of this study was to determine the number of cases of hypoglycemia cared for annually in France in an inpatient setting and to estimate the annual financial impact of hospitalizations.
  
  
  METHODS
  The number of hypoglycemias seen annually by physician s in France and the frequencies of hospitalizations for hypoglycemia were determined from a literature search. Complementary data on costs were obtained from the national PMSI mission. Our sample included 817 hospital stays between 1994 and 1995.
  
  
  RESULTS
  In 1992, physicians in France cared for 40,000 episodes of hypoglycemia. There were 10,800 hospitalizations. In 9 out of 10 cases, the hospital stay lasted several days and, despite hospitalization, 1.9% of the patients died. Mean total medical cost of a hospital stay for hypoglycemia was 14,000 FF ($2,100) (median 10,000 FF, range 1,200-120,000 FF). Mean length of stay was 6.6 days.
  
  
  CONCLUSIONS
  Mean unit cost for hospital stays for hypoglycemia is high. Based on the 1993 SESI survey, the probable annual cost for the society for hospital care of patients with hypoglycemia was an estimated 108 to 151 million FF ($16-22 million) in 1995. This figure only takes into account the visible cost of caring for hypoglycemia patients. Ambulatory care was not taken into consideration. Education, for the patient and family, is fundamental for the prevention and treatment of hypoglycemia.
  
  
  CONCLUSIONS
  It is important to have this estimation due to the absence of a medicoeconomic study on ambulatory and hospital care for hypoglycemia. Complementary studies should be conducted to estimate the total annual cost of hypoglycemia in France.
authors.affiliation: Laboratoires Lilly France, Saint Cloud. marie-p.allicar@lilly.com
authors.forename: M P
authors.initials: MP
authors.lastname: Allicar
authors.forename: F
authors.initials: F
authors.lastname: Mégas
authors.forename: S
authors.initials: S
authors.lastname: Houzard
authors.forename: A
authors.initials: A
authors.lastname: Baroux
authors.forename: F
authors.initials: F
authors.lastname: Le Thai
authors.forename: B
authors.initials: B
authors.lastname: Augendre-Ferrante
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000191:economics* / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000191:economics* / Q000453:epidemiology; D005260:Female; D005602:France; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007003:Hypoglycemia / Q000191:economics* / Q000453:epidemiology; D015994:Incidence; D007331:Insulin Coma / Q000191:economics* / Q000453:epidemiology; D007902:Length of Stay / Q000191:economics*; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D010359:Patient Readmission / Q000191:economics